AIM: The goal of this article is to provide an overview of diagnostic standard operating procedures for both clinical and imaging assessment of cervical and endometrial carcinoma, sarcoma of the uterus, and primary pelvic non-Hodgkin's lymphoma. METHODS: The literature was reviewed for methods used to diagnose malignancies in the female pelvis with a special focus on the role of MRI as the imaging method of choice. Furthermore, CT findings and staging criteria for the mentioned malignancies are also provided. CONCLUSION: Whereas ultrasound still remains the imaging modality of choice in clinical practice for the early diagnosis of female pelvic malignancies, MRI is more frequently recognized as a diagnostic tool for its accuracy in tumor identification. MRI also plays a crucial role in the 3D pretreatment planning for brachytherapy especially in cervical cancer. In the future, PET/CT might achieve an important role for staging lymph nodes or distant metastases as well as tumor recurrence.
AIM: The goal of this article is to provide an overview of diagnostic standard operating procedures for both clinical and imaging assessment of cervical and endometrial carcinoma, sarcoma of the uterus, and primary pelvic non-Hodgkin's lymphoma. METHODS: The literature was reviewed for methods used to diagnose malignancies in the female pelvis with a special focus on the role of MRI as the imaging method of choice. Furthermore, CT findings and staging criteria for the mentioned malignancies are also provided. CONCLUSION: Whereas ultrasound still remains the imaging modality of choice in clinical practice for the early diagnosis of female pelvic malignancies, MRI is more frequently recognized as a diagnostic tool for its accuracy in tumor identification. MRI also plays a crucial role in the 3D pretreatment planning for brachytherapy especially in cervical cancer. In the future, PET/CT might achieve an important role for staging lymph nodes or distant metastases as well as tumor recurrence.
Authors: Natascha Wachter-Gerstner; Stefan Wachter; Evi Reinstadler; Claudia Fellner; Tomas H Knocke; Andre Wambersie; Richard Pötter Journal: Radiother Oncol Date: 2003-09 Impact factor: 6.280
Authors: Johannes C A Dimopoulos; Gertrude Schirl; Anja Baldinger; Thomas H Helbich; Richard Pötter Journal: Strahlenther Onkol Date: 2009-05-15 Impact factor: 3.621
Authors: M P Schmid; R Pötter; P Brader; A Kratochwil; G Goldner; K Kirchheiner; A Sturdza; C Kirisits Journal: Strahlenther Onkol Date: 2012-12-21 Impact factor: 3.621
Authors: M P Schmid; B Mansmann; M Federico; J C A Dimopoulous; P Georg; E Fidarova; W Dörr; R Pötter Journal: Strahlenther Onkol Date: 2013-01-25 Impact factor: 3.621